Resistant hypertension (RHTN) represents a growing clinical challenge, affecting an estimated 10–15% of patients with treated hypertension [1–3]. Its prevalence might increase in the coming years, driven by the rising burden of obesity, diabetes mellitus, chronic kidney disease (CKD), and other cardiometabolic conditions that are more prevalent in patients with RHTN than in the general hypertensive population [4,5]. Recent international guidelines have emphasized the importance of accurately identifying “true” RHTN by excluding pseudo-resistance (such as poor treatment adherence, white-coat effect, and inaccurate blood pressure (BP) measurement) as well as secondary causes of hypertension [1].
